Description
1.1 Inclusions
This Technical Information Report (TIR) provides recommendations on the application ofCGMPs for drugs, devices, biologics, and human cells, tissues, and cellular and tissuebased products during development and marketing of combination products (drugdevice,biologic-device, drug-biologic, or drug-device-biologic), in accordance with theFDA's final rule (21 CFR Part 4; 78 FR 4307, 2013—hereafter “The Rule” or “FDA's FinalRule”). These recommendations are intended to inform the adoption and application ofCGMPs for combination products.
1.2 Exclusions
The TIR does not address topics outside the realm of CGMPs. Additionally, the TIR mayinform practices for combination products marketed outside the United States, but it isnot intended, or considered to address non-U.S. requirements comprehensively.
Product Details
- Published:
- 08/14/2015
- Number of Pages:
- 28
- File Size:
- 1 file , 330 KB
